Inhibition of stearoyl CoA desaturase‐1 activity suppresses tumour progression and improves prognosis in human bladder cancer

Piao, Chiyuan; Cui, Xiaolu; Zhan, Bo; Li, Jun; Li, Zeliang; Li, Zhenhua; Liu, Xiankui; Bi, Jianbin; Zhang, Zhe; Kong, Chuize

doi:10.1111/jcmm.14114

Cited by 46 publications

(38 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCD catalyzes the biosynthesis of monounsaturated fatty acids, and its role in cancer has been previously reviewed [ 173 , 174 ]. In the years since those reviews were published, increased expression of SCD has been reported in an ever-growing list of cancer types including breast [ 57 ], colorectal [ 175 ], ovarian [ 176 ], endometrial [ 177 ], bladder [ 178 ], colorectal cancer [ 175 ], and clear-cell renal cell carcinoma [ 179 ]. Many of these recent studies have demonstrated that inhibiting SCD leads to accumulation of palmitate and stearate saturated fatty acids and reduced palmitoleate and oleate monounsaturated fatty acids [ 175 , 176 , 180 , 181 ].…”

Section: Tumor Fatty Acid Metabolism Pathways and Their Role In Cancementioning

confidence: 99%

The diversity and breadth of cancer cell fatty acid metabolism

2021

View full text Add to dashboard Cite

Tumor cellular metabolism exhibits distinguishing features that collectively enhance biomass synthesis while maintaining redox balance and cellular homeostasis. These attributes reflect the complex interactions between cell-intrinsic factors such as genomic-transcriptomic regulation and cell-extrinsic influences, including growth factor and nutrient availability. Alongside glucose and amino acid metabolism, fatty acid metabolism supports tumorigenesis and disease progression through a range of processes including membrane biosynthesis, energy storage and production, and generation of signaling intermediates. Here, we highlight the complexity of cellular fatty acid metabolism in cancer, the various inputs and outputs of the intracellular free fatty acid pool, and the numerous ways that these pathways influence disease behavior.

show abstract

Section: Tumor Fatty Acid Metabolism Pathways and Their Role In Cancementioning

confidence: 99%

The diversity and breadth of cancer cell fatty acid metabolism

2021

View full text Add to dashboard Cite

show abstract

“…Many hormones and growth factors, such as transforming growth factor β (TGF-β ) , epidermal growth factor receptor (EGFR), fibroblast growth factor receptor 3 (FGFR3), and platelet-derived growth factor (PDGF), induce the expression of SCD1 [66,67,68,69,70]. Further studies showed that the A939572-induced inhibition of SCD1 suppresses the proliferation and induces the apoptosis of cancer cells of different origins, including the kidneys, bladder, liver, colon, thyroid, and endometrium [27,71,72,73,74,75]. Similar effects were reported for other inhibitors of SCD1, including CAY10566, MF-438, and CVT-11127 in the case of breast, lung, and colorectal cancer cells [74,76,77,78].…”

Section: Scd1 Cancer Cell Proliferation and Tumor Growthmentioning

confidence: 99%

Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer

Tracz-Gaszewska

Dobrzyń

2019

Cancers

155

149

View full text Add to dashboard Cite

A distinctive feature of cancer cells of various origins involves alterations of the composition of lipids, with significant enrichment in monounsaturated fatty acids. These molecules, in addition to being structural components of newly formed cell membranes of intensely proliferating cancer cells, support tumorigenic signaling. An increase in the expression of stearoyl-CoA desaturase 1 (SCD1), the enzyme that converts saturated fatty acids to ∆9-monounsaturated fatty acids, has been observed in a wide range of cancer cells, and this increase is correlated with cancer aggressiveness and poor outcomes for patients. Studies have demonstrated the involvement of SCD1 in the promotion of cancer cell proliferation, migration, metastasis, and tumor growth. Many studies have reported a role for this lipogenic factor in maintaining the characteristics of cancer stem cells (i.e., the population of cells that contributes to cancer progression and resistance to chemotherapy). Importantly, both the products of SCD1 activity and its direct impact on tumorigenic pathways have been demonstrated. Based on these findings, SCD1 appears to be a significant player in the development of malignant disease and may be a promising target for anticancer therapy. Numerous chemical compounds that exert inhibitory effects on SCD1 have been developed and preclinically tested. The present review summarizes our current knowledge of the ways in which SCD1 contributes to the progression of cancer and discusses opportunities and challenges of using SCD1 inhibitors for the treatment of cancer.

show abstract

“…Treated cells were used for an apoptosis assay with a FITC Annexin V Apoptosis Detection Kit (BD Pharmingen) and a cell cycle assay with PI/RNase Staining Buffer Solution (BD Pharmingen), or a Cell‐Light 5‐ethynyl‐2′‐deoxyuridine (EdU) DNA Cell Proliferation Kit (Beyotime) following the manufacturers' protocols and were analysed by flow cytometry (Becton Dickinson Biosciences) as previously described …”

Section: Methodsmentioning

confidence: 99%

“…Paraffin‐embedded tissues from nude mice were cut into 4‐μm slices. Immunohistochemical analysis was performed as previously described …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Caspase recruitment domain family member 10 regulates carbamoyl phosphate synthase 1 and promotes cancer growth in bladder cancer cells

Liu

Zhang

et al. 2019

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Bladder cancer, which can be divided into non‐muscle‐invasive and muscle‐invasive bladder cancer, is the most common urinary cancer in the United States. Caspase recruitment domain family member 10 (CARD10), also named CARD‐containing MAGUK protein 3 (CARMA3), is a member of the CARMA family and may activate the nuclear factor kappa B (NF‐κB) pathway. We utilized RNA sequencing and metabolic mass spectrometry to identify the molecular and metabolic feature of CARD10. The signalling pathway of CARD10 was verified by Western blotting analysis and functional assays. RNA sequencing and metabolic mass spectrometry of CARD10 knockdown identified the metabolic enzyme carbamoyl phosphate synthase 1 (CPS1) in the urea cycle as the downstream gene regulated by CARD10. We confirmed that CARD10 affected cell proliferation and nucleotide metabolism through regulating CPS1. We indicated that CARD10 promote bladder cancer growth via CPS1 and maybe a potential therapeutic target in bladder cancer.

show abstract

Inhibition of stearoyl CoA desaturase‐1 activity suppresses tumour progression and improves prognosis in human bladder cancer

Cited by 46 publications

References 51 publications

The diversity and breadth of cancer cell fatty acid metabolism

The diversity and breadth of cancer cell fatty acid metabolism

Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer

Caspase recruitment domain family member 10 regulates carbamoyl phosphate synthase 1 and promotes cancer growth in bladder cancer cells

Contact Info

Product

Resources

About